There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097
Recruiting
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study details include: 1. The study duration will be event-driven, with an estimated duration of approximately 9 years. 2. Participants may receive study treatment until disease progression, unacceptable toxici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Research Site, Houston, Texas +1 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT06388200
Recruiting
This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP. This is a multicenter, assessor blinded and randomized study which will enroll 150 subjects.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
07/31/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Retinitis Pigmentosa
Register for Updates
Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
NCT06439485
Recruiting
To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cholangiocarcinoma, FGFR2 Fusion
Register for Updates
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
NCT06412198
Recruiting
To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Colorectal Cancer, KRAS G12C Mutations
Register for Updates
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519
Recruiting
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Epithelial Ovarian Cancer, BRCA2 Mutation, ER+ Breast Cancer, Castrate Resistant Prostate Cancer, BRCA1 Mutation, BRCA Mutation, Endometrial Cancer, Colorectal Cancer, Gastric Cancer
Register for Updates
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
NCT06358430
Recruiting
To find the highest and/or recommended dose of TROP2-CAR-NK cells combined with cetuximab in participants with MRD CRC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Colorectal Cancer, Minimal Residual Disease
Register for Updates
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
NCT06617858
Recruiting
To investigate the efficacy of AMB-05X in patients with CRC with MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Colorectal Cancer
Register for Updates
Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder
NCT06545916
Recruiting
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Cebis Usa, Llc, Houston, Texas
Conditions: Alcohol Use Disorder
Register for Updates
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984
Recruiting
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847
Recruiting
The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration for participants in both study parts is approximately 105 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Accurate Clinical Research, Inc., Houston, Texas +1 locations
Conditions: Primary Sjogrens Disease
Register for Updates
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
NCT06664879
Recruiting
To demonstrate the efficacy of targeted and tailored sequential therapy in patients with AML.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/31/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: AML
Register for Updates
Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis
NCT07109869
Recruiting
This is a Phase 3 clinical study to evaluate the efficacy, safety, and tolerability of boric acid 600 mg vaginal inserts in patients with VVC.
Gender:
FEMALE
Ages:
12 years and above
Trial Updated:
07/31/2025
Locations: TMC Life Research, Inc, Houston, Texas
Conditions: Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital, Vulvovaginal Candidiasis (VVC)
Register for Updates